Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0451
Abstract: Background Previously, we demonstrated that radiation therapy (RT) combined with Bempegaldesleukin (BEMPEG;NKTR-214), a first-in-class CD122-preferential IL-2 pathway agonist, led to enhanced anti-tumor efficacy through a T cell-dependent mechanism. However, we observed only modest systemic responses…
read more here.
Keywords:
nktr 262;
cd8;
cell;
bempeg nktr ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004218
Abstract: Background Tumor cell death caused by radiation therapy (RT) triggers antitumor immunity in part because dying cells release adjuvant factors that amplify and sustain dendritic cell and T cell responses. We previously demonstrated that bempegaldesleukin…
read more here.
Keywords:
cell;
nktr 262;
bempeg nktr;
tumor ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-3755
Abstract: Background: NKTR-262 is a novel therapeutic, which delivers intratumoral engagement of the TLR 7/8 pathway, promoting an immune stimulatory environment and local injection site tumor antigen release. When NKTR-262 is administered in combination with NKTR-214,…
read more here.
Keywords:
combination;
nktr 214;
nktr 262;
activation ... See more keywords